We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

122 hedge funds and large institutions have $154M invested in Arbutus Biopharma in 2021 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 19

73% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 22

52% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $9.51M

23% more funds holding

Funds holding: 99 → 122 (+23)

3% more capital invested

Capital invested by funds: $149M → $154M (+$4.95M)

5.95% less ownership

Funds ownership: 35.18% → 29.24% (-5.9%)

Holders
122
Holders Change
+23
Holders Change %
+23.23%
% of All Funds
1.88%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
43
Increased
38
Reduced
22
Closed
19
Calls
$14.4M
Puts
$9.51M
Net Calls
+$4.92M
Net Calls Change
-$893K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$7.84M
2
BC
Brookfield Corp
Ontario, Canada
+$4.63M
3
N
Nuveen
North Carolina
+$3.47M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.07M
5
GPP
Great Point Partners
Connecticut
+$2.6M

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$8.66M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.84M
3
SG Americas Securities
SG Americas Securities
New York
-$2.24M
4
WP
Woodline Partners
California
-$2.13M
5
Marshall Wace
Marshall Wace
United Kingdom
-$1.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
126
ExodusPoint Capital Management
New York
– -$95K -22,184 Closed
HighTower Advisors
127
HighTower Advisors
Illinois
– -$82K -19,065 Closed
HF
128
HRT Financial
New York
– -$80K -18,724 Closed
MAM
129
Meeder Asset Management
Ohio
– -$70K -16,499 Closed
LPL Financial
130
LPL Financial
California
– -$45K -10,600 Closed
PCM
131
Penserra Capital Management
California
– -$9K -2,265 Closed
AWA
132
Arkadios Wealth Advisors
Georgia
– -$4K -1,000 Closed
JWA
133
JFS Wealth Advisors
Pennsylvania
– -$4K -1,000 Closed
HI
134
Harbour Investments
Wisconsin
– -$3K -700 Closed
Federated Hermes
135
Federated Hermes
Pennsylvania
– -$3K -619 Closed
NFG
136
Next Financial Group
Texas
– -$1K -200 Closed
Carson Wealth (CWM LLC)
137
Carson Wealth (CWM LLC)
Nebraska
– +$39 +10 New
FCA
138
FinTrust Capital Advisors
South Carolina
– +$117 +30 New
RFA
139
Reilly Financial Advisors
California
– +$291 +75 New
LPWM
140
Lake Point Wealth Management
Texas
– +$388 +100 New
2 3 4 5
6

ABUS Hedge Fund Activity: Q4 2021 in Review

122 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2021, worth a combined $154M — up 3.3% from $149M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ABUS positions and 19 closed out — a net gain of 24 holders — while 38 added to existing stakes and 22 trimmed.

The largest buyer was Millennium Management, adding an estimated $7.84M. The largest seller was RTW Investments, cutting an estimated $8.66M.

  • 122 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2021, up from 99 in Q3 2021.
  • Funds reported $154M of Arbutus Biopharma stock for Q4 2021, up 3.3% quarter-over-quarter.
  • 43 funds opened new Arbutus Biopharma positions in Q4 2021 and 19 closed out, a net change of +24 holders.
  • The largest Arbutus Biopharma buyer in Q4 2021 was Millennium Management, an estimated $7.84M added.
  • The largest Arbutus Biopharma seller in Q4 2021 was RTW Investments, an estimated $8.66M sold.

Based on aggregated 13F filings for Q4 2021.